Two announcements on Monday and Thursday of last week signaled a fundamental strategic and physical shift for biopharma giant AstraZeneca, including the establishment of a new corporate headquarters in a new UK location; the shift of small molecule and biologics R&D to three strategic centers around the world; and an eventual overall headcount reduction of 5,050 between now and the end of 2016.
On Monday, March 18, the company announced its intent to focus the R&D in three places, and to fully implement these plans by 2016:
{iframe}http://siteselection.com/LifeSciences/2013/mar/astra-zeneca.cfm{/iframe}